Oruka Therapeutics
ORKA
20 hedge funds and large institutions have $2.41M invested in Oruka Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
15% more call options, than puts
Call options by funds: $169K | Put options by funds: $147K
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.24% less ownership
Funds ownership: 0.88% → 0.65% (-0.24%)
47% less capital invested
Capital invested by funds: $4.53M → $2.41M (-$2.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$145K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$107K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$34.9K |
| 4 |
Millennium Management
New York
|
+$31.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$27.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.31M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$196K |
| 3 |
AGM
Alpine Global Management
New York
|
-$49K |
| 4 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
-$30K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.6K |
ORKA Hedge Fund Activity: Q4 2021 in Review
20 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2021, worth a combined $2.41M — down 47% from $4.53M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ORKA positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $145K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $1.31M sold.
- 20 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2021, up from 19 in Q3 2021.
- Funds reported $2.41M of Oruka Therapeutics stock for Q4 2021, down 47% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q4 2021 and 4 closed out, a net change of +1 holder.
- The largest Oruka Therapeutics buyer in Q4 2021 was Acadian Asset Management, an estimated $145K added.
- The largest Oruka Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $1.31M sold.
Based on aggregated 13F filings for Q4 2021.